Hyperlipoproteinemias

Does Adding Evolocumab to Statin Tx Impact Cognitive Function?

August 17, 2017

The researchers found that the mean change from baseline over time in the raw score for the spatial working memory strategy index of executive function was −0.21 ± 2.62 and −0.29 ± 2.81 in the evolocumab and placebo groups, respectively.

Recall: Antidepressant Tablets Found in Bottle Labeled for Cholesterol Med

By August 10, 2017

While side effects of bupropion are typically minor, some patients may be at greater risk for adverse effects.

Nikita Approved to Treat Primary Hyperlipidemia, Mixed Dyslipidemia

By August 09, 2017

The efficacy of pitavastatin has been evaluated in multiple clinical studies.

Obeticholic Acid + Statin Shows Rapid Reversal of LDL Rise in NASH Patients

By August 02, 2017

The mean LDL change from baseline to Week 16 were as follows: placebo: -48 mg/dL, OCA 5mg: -40mg/dL, OCA 10mg: -40mg/dL, and OCA 25mg: -45mg/dL.

Repatha sBLA Under Priority Review for MACE Risk Reduction

By July 28, 2017

Results showed that the evolocumab group had a statistically significant 15% reduction (P<0.001) in the risk of extended MACE composite (primary) endpoint - which included hospitalization for unstable angina, coronary revascularization, heart attack, stroke or cardiovascular death - compared to placebo group.

Should Children with Familial Hypercholesterolemia Receive Statins?

By July 27, 2017

The researchers found that statins reduced the mean low-density lipoprotein (LDL) cholesterol concentration at all time points (moderate quality evidence).

Case Report: Severe Hypertriglyceridemia in a Young, Healthy Patient

July 26, 2017

Patient with hypertriglyceridemia had polymorphisms producing triglyceride risk score of 19

Continuing Statin Tx After Adverse Reaction: Is It Beneficial?

July 25, 2017

Continued statin prescription linked to lower incidence of cardiovascular events and death

Zypitamag Approved for Primary Hyperlipidemia, Mixed Dyslipidemia

By July 18, 2017

Each film-coated tablet of Zypitamag contains 1.026mg, 2.053mg, or 4.106mg of pitavastatin magnesium, which is equivalent to 1mg, 2mg, or 4mg, respectively of free base.

USPSTF: Recommendations Issued on Lifestyle Counseling for Healthy Patients

July 12, 2017

USPSTF urges doctors to talk to low-risk, in addition to high-risk, adults about lifestyle

New Diagnostic Test May Help Predict Heart Disease Risk

By June 06, 2017

Combining cholesterol uptake capacity with known cardiovascular disease risk factors also significantly improved the power of those factors to predict patients who would re-develop heart disease.

Prescriptions for High-Intensity Statins Following MI Increasing

June 05, 2017

Increase in percentage of beneficiaries whose first statin Rx after MI was for high-intensity dose

FDA to Review New Evolocumab Cardiovascular Outcomes Data

By June 05, 2017

Results showed that the Repatha plus statin group had a statistically significant 20% (P<0.001) reduction in hard major adverse cardiovascular events.

Statin Benefits Go Beyond Lowering Cholesterol, Study Finds

By May 26, 2017

Multiple regression analysis showed that those taking statins had a 2.4% lower left ventricular mass and lower left and right ventricular volumes.

Are Statins Beneficial for Primary Prevention in Older Adults?

By May 23, 2017

The authors concluded that newly administered statins given for primary prevention provided no benefit to these patients with regards to all-cause mortality or CHD events.

Polypharmacy Common in Patients Nearing the End of Life

May 22, 2017

Researchers find many still prescribed long-term disease-preventing medications

Study Assesses Global Burden of Cardiovascular Disease

May 18, 2017

Estimated 422.7 million prevalent cases of CVD, 17.92 million CVD deaths in 2015

Is It Really a Statin-Related Side Effect?

May 05, 2017

Excess rate of muscle-related adverse event reports when patients are aware that statins being used

Are Statin Users at Greater Risk for Back Disorders?

By May 03, 2017

Previous research has demonstrated a link between statin use and use-related injury and arthropathies.

Is Alternate-Day Fasting Better for Weight Loss?

By May 01, 2017

The study authors observed that participants in the daily calorie restriction group achieved their prescribed energy goals whereas participants in the alternate-day fasting group ate more than prescribed on their "fast"days and ate less than prescribed on their "feast" days.

Cholesterol Combo Vytorin Now Available as Generic

By April 26, 2017

Vytorin is indicated as adjunct to diet in primary hyperlipidemia or mixed hyperlipidemia: to reduce elevated total-C, LDL-C, apo B, TG and non-HDL-C, and to increase HDL-C.

FDA Approves Once-Monthly Dosing for Praluent

April 25, 2017

The FDA approval was supported by data from the Phase 3 ODYSSEY CHOICE I study that examined Praluent 300mg every 4 weeks vs. placebo in patients with hypercholesterolemia.

For HIV Patients with Dyslipidemia, Pitavastatin Superior to Pravastatin

By April 19, 2017

The analysis found treatment with Livalo led to a statistically significant and superior reduction in LDL-C vs. pravastatin at Week 12.

Statin Eligibility with ACC/AHA vs. USPSTF Guidelines Compared

By April 18, 2017

Full application of the USPSTF recommendations would be associated with statin therapy initiation in another 15.8% (95% CI: 14-17.5) of patients vs. another 24.3% (95% IC: 22.3-26.3) of patients with full application of the 2013 ACC/AHA guidelines.

How Common are Adverse GI Events with Statin Therapy?

By April 17, 2017

The analyses found no statistically significant difference between statin use and lower gastrointetinal conditions in constipation (OR 0.96, 95% CI: 0.87-1.05; P=0.33), abdominal pain (OR 0.95, 95% CI: 0.88-1.02; P=0.15), or colitis (OR 1.02, 95% CI: 0.91-1.14; P=0.73).

Inclisiran for Reducing LDL Cholesterol in Patients at High CV Risk

By April 13, 2017

Kausik, KR, et al. "Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol"

Metabolic Outcomes in Trans Teens Receiving Cross-Sex Hormones

April 12, 2017

The researchers found that of the 72 subjects taking testosterone, at each visit significant increases in hemoglobin/hematocrit levels and BMI were recorded, as was a decrease in high-density lipoprotein level.

AHA: Awareness of Cholesterol Management Lacking in At-Risk Patients

April 12, 2017

Patients felt least informed about what their target body weight should be, the differences between the types of cholesterol, and goals for cholesterol management.

Evinacumab Gets Breakthrough Status for Severe Form of Hypercholesterolemia

By April 06, 2017

Regeneron previously reported positive interim Phase 2 results which showed that evinacumab added to current lipid-lowering therapy reduced low-density lipoprotein cholesterol (LDL-C) levels by an additional 55%.